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Abstract
Background Caveolin-3 (Cav3) is the principal structural component of caveolae in skeletal muscle. Dominant pathogenic
mutations in the Cav3 gene, such as the Limb Girdle Muscular Dystrophy-1C (LGMD1C) P104L mutation, result in substantial
loss of Cav3 and myopathic changes characterized by muscle weakness and wasting. We hypothesize such myopathy may also
be associated with disturbances in mitochondrial biology. Herein, we report studies assessing the effects of Cav3 deficiency on
mitochondrial form and function in skeletal muscle cells.
Methods L6 myoblasts were stably transfected with Cav3P104L or expression of native Cav3 repressed by shRNA or
CRISPR/Cas9 genome editing prior to performing fixed/live cell imaging of mitochondrial morphology, subcellular fractionation
and immunoblotting, or analysis of real time mitochondrial respiration. Skeletal muscle from wild-type and Cav3/ mice was
processed for analysis of mitochondrial proteins by immunoblotting.
Results Caveolin-3 was detected in mitochondrial-enriched membranes isolated from mouse gastrocnemius muscle and L6
myoblasts. Expression of Cav3P104L in L6 myoblasts led to its targeting to the Golgi and loss of native Cav3 (>95%), including
that associated with mitochondrial membranes. Cav3P104L reduced mitochondrial mass and induced fragmentation of the mi-
tochondrial network that was associated with significant loss of proteins involved in mitochondrial biogenesis, respiration,
morphology, and redox function [i.e. PGC1α, succinate dehyrdogenase (SDHA), ANT1, MFN2, OPA1, and MnSOD). Further-
more, Cav3P104L myoblasts exhibited increased mitochondrial cholesterol and loss of cardiolipin. Consistent with these
changes, Cav3P104L expression reduced mitochondrial respiratory capacity and increased myocellular superoxide production.
These morphological, biochemical, and functional mitochondrial changes were phenocopied in myoblasts in which Cav3 had
been silenced/knocked-out using shRNA or CRISPR. Reduced mitochondrial mass, PGC1α, SDHA, ANT1, and MnSOD were also
demonstrable in Cav3/ mouse gastrocnemius. Strikingly, Cav3 re-expression in Cav3KO myoblasts restored its mitochondrial
association and facilitated reformation of a tubular mitochondrial network. Significantly, re-expression also mitigated changes
in mitochondrial superoxide, cholesterol, and cardiolipin content and recovered cellular respiratory capacity.
Conclusions Our results identify Cav3 as an important regulator of mitochondrial homeostasis and reveal that Cav3 defi-
ciency in muscle cells associated with the Cav3P104L mutation invokes major disturbances in mitochondrial respiration and en-
ergy status that may contribute to the pathology of LGMD1C.
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Introduction
Caveolae are inwardly-directed flask-like invaginations of the
plasma membrane that are enriched in cholesterol and
sphingolipids. Their structural integrity is critically dependent
upon the presence of caveolin (Cav), an integral membrane
protein that avidly binds cholesterol within the caveolar mem-
brane domain.1,2 Cav is present as three isoforms: Cav1 and
Cav2, which are co-expressed in most cell types and capable
of forming hetero-oligomers, and Cav3 whose expression is
exclusive to skeletal, smooth, and cardiac muscle and capable
of homo-oligomerisation.3,4 In addition to binding cholesterol,
Cav isoforms also possess a scaffolding binding domain that
allows them to bind and/or recruit functionally diverse
molecules to caveolae where their modulation can affect
numerous downstream signalling pathways and cellular re-
sponses.5–8 Indeed, the importance of Cav1 and Cav3 in
influencing diverse cell/tissue processes is highlighted by stud-
ies in Cav1-deficient and Cav3-deficient mice, which are not
just devoid of cell surface caveolae but exhibit a range of phe-
notypes including muscle and pulmonary dysfunction and im-
paired lipid homeostasis.9 The significance of Cav3 in skeletal
muscle physiology is further underscored by the numerous
pathogenic mutations that have been identified in the CAV3
gene that result in muscle caveolinopathies, including limb gir-
dle muscular dystrophy type 1C (LGMD1C), rippling muscle
disease, familial hypertrophic cardiomyopathy, distal myopa-
thy and isolated hyperCKemia10. Significantly, dominant mu-
tations in Cav3 are associated with reduced muscle Cav3
content that might have important implications for numerous
Cav3-dependent sarcolemmal processes and consequently
upon disease severity.10
The single missense amino acid substitution from a proline
to a leucine at residue 104 (Cav3P104L) is frequently associ-
ated with LGMD1C.10 Under normal circumstances, homo-
oligomers of wild-type (WT) Cav3 would be routed to the
sarcolemma/T-tubule membrane via the ER-Golgi pathway,
but this targeting is notably defective for the Cav3P104L mu-
tant, which is retained within the Golgi network.11 Impor-
tantly, the formation of oligomers between WT and mutant
Cav3 also impairs delivery of native Cav3 to the cell surface,
which becomes targeted along with the mutated Cav3 pro-
tein for degradation by the ubiquitin-proteasome pathway.
In line with this, analyses of muscle from LGMD1C patients
reveal a substantial decline (~95%) in Cav3 abundance,12 loss
of cell surface caveolae, and marked disorganization of the T-
tubule system.13 These myopathic changes are likely to con-
tribute to the atrophy and weakness of muscle seen in these
patients and can be phenocopied in mice that are transgenic
overexpressors for the Cav3P104L mutant.14 While little is still
known as to how the Cav3P104L mutation might promote
muscle atrophy. it has been reported that Cav3 represses
myostatin signalling by blunting activation of its Type I cell
surface receptor.15 Myostatin is a well-known negative
regulator of muscle mass,16 and this repression restrains the
activity of a pathway that would otherwise promote muscle
atrophy. This restraint is likely to be alleviated in muscle ex-
pressing the Cav3P104L mutant owing to the substantial reduc-
tion in Cav3 that would result in a concomitant increase in
myostatin signalling.15 Interestingly, very recent work has
also linked expression of Cav3P104L in C2C12 myotubes to re-
duced activation of Akt (a key insulin signalling intermedi-
ate17) and a diminution in glucose uptake and glycogen
synthesis.18 These latter observations raise the possibility
that disturbances in fuel and energy metabolism may also
be contributing factors to the pathology of LGMD1C.
While expression of Cav proteins has been traditionally
associated with cell surface caveolae, there is now consider-
able evidence supporting their localization within different
subcellular compartments. Cav1, for example, is detectable
in the Golgi,19 endosomes,20 cytosolic lipid droplets,21 se-
cretory vesicles, and in close apposition to mitochondria
in airway epithelial cells.22,23 Cav1 is also an integral com-
ponent of mitochondrial associated membranes in mouse
liver where it has been implicated in the regulation of intra-
cellular steroid and lipoprotein metabolism.24 More re-
cently, Volonte et al. demonstrated that Cav1 is recruited
to mitochondria during oxidative stress where it associates
with a matrix-oriented mitochondrial protease, AFG3L2, an
interaction thought to form part of a stress-response mech-
anism that may help maintain mitochondrial quality con-
trol.25 The notion that mitochondrial localized Cav may
confer protection against cell stress and injury is also sup-
ported by studies in cardiomyocytes in which overexpres-
sion and increased localization of Cav3 to mitochondria
are associated with enhanced calcium tolerance, improved
respiratory function, and suppressed generation of reactive
oxygen species (ROS).26,27 Whether Cav3 similarly associates
with mitochondria in skeletal muscle and whether loss of
Cav3 impairs mitochondrial function is currently unknown.
However, given that mitochondrial dysfunction has been
linked to muscle atrophy during muscle inactivity,28 distur-
bances in mitochondrial biology may also be a feature con-
tributing to the development and progression of muscle-
wasting conditions. In support of this proposition, there is
growing evidence linking mitochondrial dysfunction to a
number of muscular dystrophies, including Duchenne, spinal
muscular atrophy, and the calpainopathy that induces limb
girdle muscular dystrophy Type 2A (LGMD2A).29–32 Whether
it is also a trait of caveolinopathies such as LGMD1C has
not yet been documented, but studies in cultured myo-
blasts and mice expressing the Cav3P104L mutation have re-
ported disordered glucose metabolism18 and altered
expression of a number of mitochondrial proteins that reg-
ulate diverse aspects of mitochondrial structure and func-
tion.11 Precisely how these changes are linked to Cav3
dysfunction remain unclear, but we hypothesize that Cav3
is closely associated with mitochondria in skeletal muscle
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cells and that its dysfunction/loss, induced by the Cav3P104L
mutation, impairs mitochondrial form and function with im-
portant consequences for key energy-dependent processes
(e.g. protein synthesis) that may be significant in the pa-
thology of LGMD1C. The studies described herein have
tested this hypothesis.
Materials and methods
Chemicals and reagents
α-Minimal essential medium (MEM), Dulbecco’s modified
Eagle’s medium, OPTI-MEM, Lipofectamine 2000, and
antibiotic/antimycotic solution were from Invitrogen. Earle’s
Balanced Salt Solution was obtained from Sigma-Aldrich.
Foetal bovine serum was purchased from BioSera (France).
Restriction enzymes and other DNA-modifying enzymes
were purchased from either New England Biolabs or Roche
Diagnostics. Olignucleotides were purchased from the Uni-
versity of Dundee Oligo Synthesis Service (University of
Dundee).
Animals
As with other Cav3 knockout mouse strains that have been
reported in the literature,33,34 the mice used in the current
study were generated by targeting exon-2 of the Cav3 gene
using the gene targeting approach detailed previously.35 Mice
were held according to the German guidelines for the care
and use of laboratory animals and experiments approved by
the Saarland’s institutional Animal Care and Use Committee.
The phenotype of Cav3/ mice has been well documented,9
but adult mice exhibit myopathic changes resembling those
described in patients with LCMD1C.13 These include muscle
atrophy and changes in muscle ultrastructure (as highlighted
by disorganization of the T-tubule system, diminished muscle
fibre size, and increased fibre necrosis) as well as reduced
muscle function as judged by a significant decline in grip
strength.15,33 Despite muscle degeneration, Cav3/ mice
have been shown to gain visceral fat with age contributing
to an increase in body weight.36 In line with this latter report,
the adult (15–20 weeks of age) male Cav3/ mice used in
the present study were slightly heavier (34.7 + 0.9 g body
weight, mean + SEM, n = 5) than age-matched WT Cav3+/+
mice (29.1 + 0.2 g body weight, mean + SEM, n = 5). Mice
were anaesthetized with an overdose of isoflurane, and the
thoracic aorta was cut. Gastrocnemius muscle was excised
from hind limbs and rapidly frozen in liquid N2 and stored
at 80°C until required. For some experiments, C57BL/6 mice
(15–20 week old) maintained at the University of Dundee in
compliance with UK Home Office Animals (Scientific Proce-
dures) Act 1986 were killed by CO2 inhalation and cervical
dislocation and gastrocnemius muscle excised from hind
limbs and processed immediately for histochemical staining
or isolation of mitochondrial membranes.
Muscle cell culture
L6 muscle cells were cultured as described previously17 in α-
minimal essential medium containing 2% (v/v) foetal bovine
serum and 1% (v/v) antibiotic/antimycotic solution (100
units/mL penicillin, 100 μg/mL streptomycin, 250 ng/mL
amphotericin B) at 37°C with 5% CO2. Consistent with previ-
ous studies,37–39 muscle cells expressing Cav3P104L or in which
Cav3 had been depleted using shRNA or CRISPR/Cas9 gene
editing exhibit reduced fusion capacity. Consequently, com-
parative analyses of WT muscle cells and those in which
Cav3 expression had been modified were conducted in myo-
blasts at Day 4 post-seeding. For the purpose of the current
studies, the term ‘muscle cells’ has been used interchange-
ably with myoblasts.
Mitochondrial membrane isolation
Mitochondrial membranes and cytosolic fractions were pre-
pared from mouse skeletal muscle as previously described.40
Briefly, gastrocnemius muscle was dissected and diced into
small pieces (~50 mg) using scissors and subsequently ho-
mogenized using 20 strokes of an Eppendorf homogenizer.
The homogenate was centrifuged at 700 g for 10 min at
4°C; the supernatant was transferred to a new tube and
the pellet discarded. The supernatant was then centrifuged
at 10 000 g for 20 min at 4°C, and the resulting supernatant
(cytosolic fraction) was kept for further analysis. The
mitochondrial-enriched membrane pellet was washed twice
with phosphate-buffered saline (PBS) prior to being resus-
pended in lysis buffer. The mitochondrial and cytosolic frac-
tions were then used for western blot analysis.
A mitochondrial-enriched membrane fraction was ob-
tained from L6 myoblasts using a mitochondrial isolation
kit (#89874, Thermo Fisher Scientific) according to the man-
ufacturer’s instructions. Typically, cells were grown until
confluence in 10 cm dishes. Muscle cells were harvested
and subsequently homogenized using an Eppendorf
homogenizer. The homogenized cell material was subject
to centrifugation at 750 g for 10 min at 4°C. The resulting
supernatant was subject to 14 000 g for 15 min at 4°C
and stored at 20°C. The final pellet was an enriched
mitochondrial fraction that was separated from the super-
natant (cytosolic fraction). The mitochondrial pellet was
solubilized in radioimmunoprecipitation assay buffer and
stored at 20°C.
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Sodium dodecyl sulphate polyacrylamide gel
electrophoresis and immunoblotting
Following appropriate experimental treatments, muscle cells
were washed twice with ice-cold PBS and then lysed as de-
scribed previously.17 Protein concentrations in lysates and mi-
tochondrial membrane preparations were determined using
the Bradford method.41 Cell lysates and membrane prepara-
tions were subject to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and separated proteins trans-
ferred onto PVDF membrane (Millipore) prior to incubation
with the following primary antibodies at a dilution of 1:1000
except where indicated otherwise: actin (#A5060, 1:5000)
was obtained from Sigma; ANT-1 (#ab180715) and PGC1α
(#ab54481) were from Abcam; MFN1 (#MMS-5021) was pur-
chased from Biolegend; Mitofusin 2 (MFN2) (#SC100560),
succinate dehyrdogenase (SDHA) (#SC98253), and GAPDH
(#SC32233, 1:5000) were purchased Santa Cruz; TOM20 (#
42406S), voltage-dependent anion channel (VDAC) (#4661S),
HA (#2367S), BiP (#C50B12), COX4 (#4580S), Catalase
(#14097), Cytochrome C (#11940), RCAS1 (#12290), and
manganase superoxide dismutase (MnSOD) (#D9V9C) were
all purchased from Cell Signalling Technology; Cav1
(#610058), Cav3 (#610421), DLP1/Drp1 (#611112), and
OPA1 (#612607) were from BD Biosciences. The α-subunit
of the Na,K-ATPase antibody was from Developmental Studies
Hybridoma Bank (University of Iowa). The puromycin anti-
body was from Kerafast (Boston, USA). Primary antibody de-
tection was performed using appropriate horse-radish
peroxidase (HRP) conjugated secondary mouse (#7076S) or
rabbit (#7074S) antibodies (1:5000) purchased from Cell Sig-
nalling Technology and visualised using enhanced chemilumi-
nescence (Pierce-Perbio Biotech, Tattenhall, UK) by exposure
to autoradiographic film (Konica Minolta (Tokyo, Japan) or
LICOR detection, respectively. Quantification of the immuno-
blot signals was carried out using Image J (NIH).
Generation of stable caveolin-3 silenced, caveolin-3
knockout L6 myoblasts, and expression of
HA-GFP-Cav3P104L, HA-GFP-CAV3, and
mCherry-IRES-Cav3
Stable L6 Cav3 silenced cell lines were generated in a manner
similar to that described previously42 using the pLKO.1-puro
vector and oligonucleotides indicated in Table 1. A non-
targeting control hairpin sequence was also included in these
experiments (Table 1). Stable cell lines were established using
early passage cells and, once established, were only used for
a maximum of five passages.
For the generation of the Cav3 IRES mCherry plasmid, the
WT Cav3 gene was cloned into a pcDNA5D FRT/TO IRES
mCherry vector [University of Dundee, MRC PPU Reagents
and Services (DU50336)] using BamHI and XhoI restriction
sites. This was transiently transfected into myoblasts using li-
pofectamine 3000 according to the manufacturer’s instruc-
tions. Expression of the vector was initiated by incubation
of cells with tetracycline at 1 μg/mL for 24 h.
Myoblasts lacking Cav3 were infected with retroviral parti-
cles containing the pBABE hygro 3xHA GFP vector [University
of Dundee, MRC PPU Reagents and Services (DU55543)] into
which the Cav3 gene had been cloned using BamHI and NotI
restriction sites. The pBABE hygro 3XHA construct was co-
transfected with GAG/POL and VSV-G expression plasmids
(Clontech, Saint-Germain-en-Laye, France) into HEK 293T cells
for the production of retroviral particles using Lipofectamine
2000 (Life Technologies) according to the manufacturer’s in-
structions. The virus was harvested 48 h after transfection
and applied to myoblasts in the presence of 10μg/ml
polybrene. Positive stable transformants were selected
for using 500 μg/mL hygromycin and subsequently main-
tained in 50 μg/mL hygromycin thereafter.
For the generation of muscle cells expressing Cav3P104L,
the proline 104 residue in the Cav3 gene within the pBABE
hygro GFP vector was mutated to leucine using the NEBuilder
HiFi DNA assembly kit as per the manufacturer’s instructions
using the oligonucleotides indicated in Table 1.
Deletion of caveolin-3 in L6 muscle cells using
CRISPR/Cas9 Genome Editing
For cellular knockout of Cav3, specific sense and antisense
guide RNA (gRNA) were designed (Table 1) to target exon1
of the CAV3 gene (NC_005103.4) that were cloned into
vectors supplied by the Division of Signal Transduction Ther-
apy (University of Dundee). CRISPR/Cas9-mediated deletion
of Cav3 was accomplished by transfecting vectors containing
the paired guides and Cas9 D10A into 106 L6 myoblasts
using polyethylenimine and selected for with 4 μg/mL puro-
mycin over 48 h. After the initial selection process, a single
colony was selected using FACS single cell sorting and Cav3
deletion in myoblasts confirmed by western blotting and
immunofluorescence.
Fixed and live cell imaging
For imaging of mouse skeletal muscle, gastrocnemius muscle
was fixed in 4% (w/v) paraformaldehyde overnight, washed
twice in PBS, and left in 30% (w/v) sucrose overnight. Muscle
was covered in OCT mountant, frozen, and cryo-sectioned (20
μm thickness) using a Leica cryostat. Muscle sections were in-
cubated with Cav3 and TOM20 antibodies for 1 h and subse-
quently incubated with Alexa Fluor 488-conjugated (#A-
11029) and Alexa Fluor conjugated 594 conjugated (#A-
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11037) secondary antibodies (1:500) for 1 h and imaged using
a Zeiss 710 Confocal Microscope.
For fixed cell imaging
Cells were grown to 70% confluence in 12-well dishes on
13 mm coverslips and fixed in 4% (w/v) paraformaldehyde
in PBS for 15 min at room temperature. Cells were perme-
abilized in PBS with 0.1% (v/v) Triton and blocked using 10%
(v/v) goat serum in PBS for 60 min. Coverslips were then
probed with Cav3 (1:300) and RCAS1 (1:400) antibodies for
1 h at room temperature in PBS containing 0.2% (w/v) bovine
serum albumin and 0.02% (w/v) sodium azide. Coverslips
were then washed three times and incubated with Hoechst
(DNA stain 1:10 000) and secondary antibodies (1:500) conju-
gated to Alexa Fluor 488 or 594 for 1 h. Coverslips were finally
washed three times with PBS and placed face down onto
glass microscope slides with a drop of ProLong Diamond
Antifade Mountant and sealed with nail varnish. Cells were
imaged using a Zeiss 710 microscope.
For live cell imaging
Cells were seeded into μ-Slide 8-well chamber slides (ibidia,
UK) and washed with fresh phenol red free MEM prior to in-
cubation with 300 nM Mitospy Green FM (BioLegend, UK) or
MitoTracker DeepRed FM (BioLegend, UK) for experiments
with cells expressing GFP. Mitochondrial morphology was vi-
sualized in real time using a Zeiss 710 confocal microscope
with a 60× oil-immersion objective 37°C in a 5% CO2 chamber
with excitation/emission set at 480 and 520 nm for Mitospy
Green FM or 644 and 665 nm for Mitotracker Deep Red
FM. For measurement of mitochondrial length, confocal im-
ages were processed using Volocity 6.3 Image Analysis Soft-
ware (PerkinElmer). The software module can segment
cellular components and give measurements such as mito-
chondrial number and classify them as condensed or
elongated/tubular based on measurement of mitochondrial
length. Mitochondria were categorized as either
spheroid/fragmented in which mitochondria were equal to
or less than 1 μm in length or tubular/elongated (including
as part of a network), where mitochondrial length was
greater than 1 μm. The number of mitochondria in each
treatment condition was then determined and expressed as
a percentage. To reduce any potential bias, a number of ran-
domly chosen fields from multiple images were selected for
quantification per experimental condition with each analysis
being repeated in a minimum of three separate experiments
or as indicated in the figure legends.
Measurement of mitochondrial membrane
potential, mitochondrial DNA, and citrate synthase
activity
For measurement of mitochondrial membrane potential,
muscle cells were seeded and grown in dark-walled 96-well
Table 1 Oligonucleotide sequences
CRISPR Antisense (5’ to 3’) Sense (5’ to 3’)
Cav3 Knockout CCGAAGAGCACACAGATCTG GAG CATCAAGGACATTCACTGCA AGG
Oligos targeting the Cas9 nuclease to the Cav3 gene for double strand breaks
Short Hairpin Oligo 1 (5’ to 3’) Oligo 2 (5’ to 3’)
Cav3 (shCav3) CCGGGGATCATCAAGGACATTCACTCTCGAG
AGTGAATGTCCTTGATGATCCTTTTTG
AATTCAAAAAGGATCATCAAGGACATTCACTCTCGAG
AGTGAATGTCCTTGATGATCC
Control (shControl) CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAG
CGAGGGCGACTTAACCTTAGGTTTTTG
AATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAG
CGAGGGCGACTTAACCTTAGG
Oligos (5’ to 3’) are composed of sense and antisense sequences (boldface) with added overhangs to facilitate cloning into pLKO.1 puro,
separated by a hairpin loop (underlined).
NEBuilder HiFi DNA Forward (5’to 3’) Reverse (5’ to 3’)
Fragment 1 acaagtccggactcgATGATGACCGAAGAGCACACAG tagctcttaATGCAGAGCACC ACGGCC
Fragment 2 ctctgcatTAAGAGCTACCTG ATTGAG cacattccacagggcTTAGTGATG GTGGTGATG
Overlapping primers incorporating the (P104L) mutation were designed for two Cav3 gene fragments that were then joined together and
ligated into the vector using the NEBuilder HiFi kit.
Gene Analysis Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’)
COX4 (Mouse) TTAACGAGAGCTTCGCCGAG GAGGCCACATAAGACCCCAA
ND4 (Mouse) AGCTCAATCTGCTTACGCCA GCTGTGGATCCGTTCGTAGT
COX4 AATGTTGGCTACCAGGGCAC GGGTAGTCACGCCGATCAAC
ND4 GAGGCAACCAAACAGAACGC ATCATGTTGAGGGTAGGGGGT
Cardiolipin
Synthase (CLS)
GATACCGAACTCTGCCAAC GAAGCTGCCACCAAAATTAAC
Phosphatidylglycerol
phosphate (PGP)
ACTCCTCCGACTCCTTATCC ACCTCCACTGTGTCATCACC
PTPM1 GAAGGAATGGAAGAATGTGGG GACTGGTACTTGAGAGCAAAC
CPD-DAG Synthase CTCAGTCACATCTTGTCATCC AGAAGAAACCACCAATGAATCC
Tafazzin CTCCTGAGTAGTGGAGGACA TTCATATACTTGGTCCAGAAGCA
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dishes until confluent for 4 days. Cells were washed with PBS
and in some experiments also treated with 5 μM FCCP (as a
positive stimulus for collapsing the mitochondrial potential)
prior to treatment with JC-10 (20 μM) and incubated at 37°
C, in 5% CO2 atmosphere for 45 min. The fluorescent intensi-
ties for both monomeric and J-aggregates of JC-10 were mea-
sured with excitation/emission set at 490/525 nm for
monomer measurement and 540/595 nm for measurement
of aggregates using a CLARIOstar plate reader prior to calcu-
lating the aggregate/monomer ratio.
For analysis/quantification of mitochondrial DNA, DNA was
isolated from myoblasts using the DNeasy Blood and
Tissue Kit as per themanufacturer’s instructions. Equal amounts
of DNA (100 ng) from each sample were then subject to quanti-
tative polymerase chain reaction (qPCR) using the Syber Green
method with primers designed to target genes encoded by nu-
clear DNA (COX4) and mitochondrial DNA (ND4). Data were
expressed as a ratio of the ΔΔCt ND4 to the ΔΔCt of COX4.
The forward and reverse primer sequences for the different
gene targets are indicated in Table 1.
Citrate synthase (CS) activity was measured using a kit pur-
chased from Sigma Aldrich, UK (MAK193). Muscle cells were
treated as described above, and whole cell extracts were pre-
pared at the end of the respective treatments. Thirty micro-
grams of cell extract protein was used for each enzymatic
analysis (with measurements being conducted in triplicate
for each experimental condition) at room temperature in
96-well dishes. Enzyme activity was measured spectrophoto-
metrically (at absorbance wavelength of 412 nm) using a
μQUNT BIOTEK plate reader from LabTech. CS activity was
calculated as per manufacturer’s instructions.
Analysis of reactive oxygen species
For mitochondrial ROS quantification, cells were seeded into
dark-walled 96-well dishes and allowed to grow to confluence.
Prior to analysis, cells werewashedwith PBS and then incubated
with a fluorescent mitochondrial targeted superoxide probe
(MitoSOX, 5 μM) at 37°C in a 5% CO2 atmosphere for 30 min.
Upon binding superoxide, MitoSOX becomes fluorogenic emit-
ting red fluorescence, which was quantified using a CLARIOstar
plate reader at peak excitation/emission wavelengths of
510/580 nm and normalized to cellular protein.
Mitochondrial respiration
Mitochondrial bioenergetics were measured in L6 myoblasts
using a Seahorse XF24 analyser. WT L6 myoblasts or those
that had been genetically manipulated (as indicated in the fig-
ure legends) were cultured on Seahorse culture plates and
used to analyse basal respiration, adenosine triphosphate
(ATP)-Linked respiration, maximal respiratory capacity, and
non-mitochondrial respiration using modulators of cell respi-
ration. Oligomycin (1 μM), FCCP (carobyl cyanide p-
trifluoromethoxyphenylhydrazone) (2 μM), rotenone (1
μM), and Antimycin (2 μM) were injected at the points indi-
cated for ~6 min prior to measurement of oxygen consump-
tion. The indicated mitochondrial parameters were
normalized to cell protein.
Analysis of cellular protein synthesis
Protein synthesis was measured as described by Goodman
et al,43 by assaying puromycin incorporation into newly syn-
thesized peptides. Briefly, myoblasts were pre-incubated in
the absence or presence of cycloheximide (50 μg/mL) prior
to incubation with or without 1 μM puromycin for 15 min. At
the end of this period, cells were lysed and lysates subjected
to SDS-PAGE and immunoblotting of PVDF membranes with
a monoclonal antipuromycin antibody followed by incubation
and detection with an antimouse HRP secondary antibody.
Cholesterol Measurement
Cholesterol was quantified using the Thermo Amplex Red cho-
lesterol assay kit according to the manufacturer’s specifica-
tions. Twenty micrograms of whole cell lysate or 5 μg of
mitochondrial-enriched fractions were added to Amplex Red
assay solution, which contains 300 μM Amplex Red reagent,
2 U/mL HRP as well as 2 U/mL cholesterol oxidase, 0.2 U/mL
cholesterol esterase, 0.1 M of potassium phosphate, pH 7.4,
0.05 mM cholic acid, and 0.1% triton X-100. After incubation
of samples with an Amplex red assay solution for 30 min at
37°C protected from light, fluorescence was measured using
a CLARIOstar plate reader set at 530/590 nm (excitation/emis-
sion). The relative concentrations of cholesterol were
calculated using a calibration curve. Cholesterol abundance
was presented as a fold change relative to control WT cells.
Cardiolipin analysis
For analysis of cardiolipin, muscle cells were grown in dark-
walled 96-well dishes or μ-Slide 8-well chamber slides until
70–80% confluent. Cells were subsequently stained with
100 nM 10-N-Nonyl Acridine Orange (NAO) for 30 min
(protected from light) at 37°C with 5% CO2. At the end of this
incubation period, cells were washed and the fluorescence in-
tensity quantified using a CLARIOstar plate reader with
excitation/emission set at 450/640 nm and normalized to
the protein amount. Alternatively, muscle cells incubated
with NAO were also incubated for the same period with
Mitotracker DeepRed (to prevent overlap of fluorescence
emissions with NAO). Cells were subsequently visualized
using a Zeiss 710 confocal microscope at 37°C with 5% CO2,
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and 12-bit images were obtained to attain higher pixel infor-
mation allowing measurement and comparison of fluores-
cence intensity of NAO, normalized against Mitotracker
Deep Red fluorescence intensity.
Statistical analyses
Statistical analysis was performed using GraphPad Prism ver-
sion 7 software using one-way analysis of variance and Tukey
post hoc test for multiple comparisons. Values were consid-
ered significant at P < 0.05.
Results
Caveolin-3 is detectable within
mitochondrial-enriched membranes from mouse
skeletal muscle and L6 myoblasts
To assess whether expression of Cav3 has any impact upon
mitochondrial function in skeletal muscle cells, we initially in-
vestigated if it might be resident within mitochondrial-
enriched membrane fractions (MF) prepared from mouse
gastrocnemius muscle and L6 myoblasts. Compared with a
crude mouse muscle homogenate (CH), we observed
immunoenrichment in the MF of VDAC, an outer mitochon-
drial membrane protein; TOM20, a key subunit of the TOM
complex that is responsible for recognition and translocation
of cytosolic synthesized mitochondrial preproteins; and Cyto-
chrome C oxidase, a component of the mitochondrial respira-
tory chain (Figure 1A). It is important to stress that this
comparative analysis of protein abundance in the CH and
MF fractions is based on the relative signals obtained for
equivalent protein loading (10 μg) on SDS-gels for immuno-
blotting studies. Also noteworthy was our observation that
actin (a cytosolic protein marker), the alpha subunit of the
Na,K-ATPase (a well-established plasma membrane marker),
RCAS1 (a Golgi marker44), and BiP [a major endoplasmic retic-
ulum (ER) chaperone protein] were barely detectable in our
isolated mitochondrial fractions indicating that these were
largely free of membranes from other subcellular compart-
ments. Strikingly, however, while we could detect an immu-
noreactive band for Cav3 in the CH, we also detected Cav3
in the MF fraction indicating that it is likely to be closely asso-
ciated with membranes of mitochondrial origin. This latter
proposition is further supported by immunohistochemical
analysis, which showed that Cav3 and TOM20 costaining
was detectable in muscle sections prepared from mouse gas-
trocnemius (Figure 1B). Although skeletal muscle also ex-
presses Cav1, the abundance of this isoform was
significantly less than that of Cav3 (Figure 1A). Consistent
with this proposition, while Cav3 was detected in isolated
MF from three separate mouse muscle preparations by im-
munoblotting, Cav1 immunoreactivity was difficult to detect
even with prolonged exposure of blots. Ratiometric analysis
of each Cav isoform relative to mitochondrial VDAC showed
that Cav3 abundance in the MF was ~18-fold greater than
Cav1 (Figure 1C). Both Cav isoforms and VDAC were largely
absent from an actin-enriched cytosolic fraction from mouse
gastrocnemius (Figure 1C).
To further substantiate the observed mitochondrial-Cav3
association that we see in mouse muscle, we utilised a non-
mechanical, reagent-based method that allows isolation of
mitochondria from rat L6 myoblasts. The MF isolated by this
procedure is, by comparison with a whole cell lysate (WCL)
or cytosolic (cyto) fraction, highly enriched in VDAC, SDHA,
and TOM20, but depleted of cytosolic (actin), plasma mem-
brane (Na,K-ATPase), ER (BiP), and lysosomal (Lamp1) protein
markers. Furthermore, while we could detect Cav3 in the
WCL, we also observed that its abundance was enriched
within the MF from L6 cells (Figure 1D). Consistent with this
observation, in separate experiments utilising L6 myoblasts
overexpressing GFP-tagged Cav3, we could visualize
costaining of GFP-Cav3 with membranes structures that had
been stained with Mitotracker Red, a fluorescent dye that
specifically labels up mitochondria within live cells (Supporting
Information, Figure S1).
Cav3P104L localizes to the Golgi in L6 muscle cells
and affects mitochondrial morphology
To assess how expression of the Cav3P104L mutation might
impact upon mitochondrial biology, we expressed GFP-
tagged versions of WT Cav3 and the Cav3P104L mutant in L6
myoblasts and explored how their localization compared with
that of endogenously expressed Cav3. Figure 2A shows that
native Cav3 localizes to the peripheral boundary of myo-
blasts, which most likely reflects plasma membrane labelling
but was also detectable within myoblasts. A very similar dis-
tribution was observed for ectopically expressed WT-Cav3-
GFP indicating that the GFP tag does not interfere with the
cellular targeting/localisation of Cav3. By comparison, while
surface and intracellular labelling of the GFP-tagged Cav3P104L
mutant was very modest, it was predominantly perinuclear in
localization. Previous studies have suggested that the P104L
mutation leads to retention of unstable Cav3 aggregates
within the Golgi complex.45 Consistent with this observation,
co-immunostaining of myoblasts for RCAS1 showed that this
Golgi protein strongly colocalized with the Cav3P104L mutant,
but not with native or ectopically expressed GFP-tagged WT-
Cav3 proteins (Figure 2A).
Because native Cav3 was detectable within membranes
of mitochondrial origin and we find that the Cav3P104L
mutant congregates within the Golgi, we subsequently
assessed its impact on mitochondrial morphology. For
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this, we performed live cell imaging to visualize mitochon-
dria using Mitotracker DeepRed, which is excluded from
nuclei but accumulates within mitochondria. Myoblasts ex-
pressing the empty vector or that encoding the GFP-tagged
WT-Cav3 exhibited mitotracker staining in which the mito-
chondria appeared predominantly (~65%) tubular/elongated
(including being part of a network) and greater than 1 μm
in length. By contrast, myoblasts expressing Cav3P104L show
a striking shift in mitochondrial morphology to one that was
largely fragmented/spheroid (>60%) in which mitochondria
were equal to or less than 1 μm in length (Figure 2B
and 2C).
Effects of expressing CavP104L on mitochondrial
function
To determine whether the observed shift in mitochondrial
morphology is accompanied by changes in mitochondrial
function, we studied cell respiration in myoblasts in real time
using a Seahorse extracellular flux analyser. This approach
measures oxygen consumption rates (OCR) before and after
addition of compounds that target Complex I and III of the re-
spiratory chain, the ATP synthase, or FCCP [which uncouples
mitochondrial oxidative-phosphorylation (OXPHOS)] to allow
analysis of numerous mitochondrial parameters. Myoblasts
expressing WT-Cav3 or those expressing the empty vector
(EV) exhibit very similar OCR traces, whereas those
expressing Cav3P104L display a significant reduction in basal,
ATP-linked, and maximal respiration (Figure 3A and 3B). It is
noteworthy that expression of Cav3P104L results in a substan-
tial reduction in cellular Cav3 as determined by immunoblot-
ting of whole cell lysates (Figure 3C), which is most likely a
result of aggregation within the Golgi and subsequent degra-
dation by the proteasome. In line with the Cav3 loss seen in
cells expressing Cav3P104L, we also observe a substantial de-
cline in Cav3 in the mitochondrial-enriched fraction prepared
from these cells (Figure 3C).
To understand what might contribute to the change in mor-
phology and the decline in mitochondrial respiratory capacity
in Cav3P104L expressing myoblasts, we assessed the expression
of a number of proteins relevant to mitochondrial biology.
While we could not detect any significant differences in VDAC,
Drp1, or Mitofusin 1 abundance, we saw significant loss of
Figure 1 Cav3 is closely associated with mitochondria in mouse skeletal muscle and rat L6myoblasts. Crude muscle homogenates (CH, 10, 30, 50 μg of
protein) and isolated mitochondrial fractions (MF, 10 μg) from mouse gastrocnemius were used for sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis and immunoblotting using antibodies to the proteins indicated (A). Mouse gastrocnemius was sectioned and stained for mitochondrial
marker TOM20 and Cav3. The field within the white box has been enlarged to highlight potential co-localization (indicated by the white arrowheads)
of TOM20 and Cav3 (B). Mitochondrial (MF, 10 μg protein) and cytosolic (Cyto, 10 μg protein) fractions isolated from gastrocnemius muscle of three
separate mice were immunoblotted with antibodies to proteins indicated. Mitochondrial abundance of Cav1 and Cav3 were quantified (using the low
exposure blots) relative to that of VDAC (C). Whole cell lysates (WCL, 5 μg protein), cytosolic (cyto, 5 μg protein) and mitochondrial fractions (MF, 5 μg
protein) prepared from L6myoblasts were subject to sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotted with antibodies to
proteins indicated (D). The blots shown in (D) are representative of three separate experimental preparations.The graphical data represent mean ±
SEM from a minimum of three separate experiments. Asterisks indicate a significant change (P < 0.05). Cav3, caveolin-3; SDHA, succinate
dehydrogenase subunit A; VDAC, voltage-dependent anion channel.
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MFN2 and OPA1. With the exception of VDAC, the latter pro-
teins are involved in regulating mitochondrial dynamics. Drp1
facilitates mitochondrial fission, whereas mitofusins and OPA1
are important regulators of mitochondrial clustering and
fusion.46 The reduction in MFN2 and OPA1 expression is con-
sistent with a shift in mitochondrial dynamics favouring in-
creased fission and is in line with the greater mitochondrial
fragmentation seen in Cav3P104L expressing myoblasts (Figure
2B and 2C). We also observed a significant decline in the abun-
dance of the adenine nucleotide translocator [ANT1, which
exchanges mitochondrial synthesized ATP for cytosolic adeno-
sine diphosphate (ADP)], SDHA, and MnSOD, which repre-
sents a key mitochondrial antioxidant enzyme. Reduction of
the latter would be anticipated to impair the capacity of cells
to detoxify mitochondrial generated superoxide, which was
significantly increased (>two-fold) in Cav3P104L expressing
myoblasts (Figure 3F). Our analysis also revealed a reduction
in the expression of PGC1α, a key transcriptional regulator of
mitochondrial biogenesis that may contribute to a decline in
mitochondrial respiratory capacity via a reduction in mito-
chondrial density.47 To explore this possibility, we assayed
the activity of CS, an enzymatic marker of mitochondrial mass.
Cav3P104L myoblasts exhibit a modest, but significant decline
in CS activity (Figure 3G).
The data presented in Figures 2 and 3 indicate that expres-
sion of Cav3P104L causes a substantial loss of native Cav3 and
that this is associated with significant disturbances in mito-
chondrial morphology, respiratory function, and expression
of key mitochondrial proteins. To further substantiate the
idea that loss of Cav3 is what is likely to drive mitochondrial
dysfunction, we performed two independent but comple-
mentary genetic approaches to stably deplete (using shRNA)
or knockout (KO, using CRISPR/Cas9 editing) Cav3 in L6 mus-
cle cells. The data presented in Supporting Information, Fig-
ures S2, S3 and S4 show that irrespective of which genetic
approach was used to reduce Cav3 in L6 myoblasts, we
Figure 2 Expression of Limb Girdle Muscular Dystrophy-1C Cav3mutation (P104L) localizes Cav3 to the Golgi and causes mitochondrial fragmentation.
L6 myoblasts expressing WT-Cav3-GFP or Cav3P104L-GFP were fixed and immunostained for RCAS1 (red, a Golgi marker) and stained with DAPI (blue,
nuclear stain) while wild-type (WT) cells not expressing GFP were immunostained using antibodies to Cav3 (green), and visualized using confocal mi-
croscopy, on three separate experiments with a minimum of 6 images per sample (A). L6 myoblasts stably expressing an empty GFP vector, WT-Cav3-
GFP or Cav3
P104L
-GFP were stained with Mitotracker Deep Red and visualized using live cell confocal microscopy. Enlarged images (derived from the
fields within the indicated red boxes) highlight changes in mitochondrial morphology (B). Mitochondrial length was quantified using Volocity software
and presented as elongated/tubular if greater than 1 μm and fragmented if less than 1 μm in length. Data are presented as mean ± SEM from a min-
imum of three separate experiments with analyses of 15–20 randomly chosen visual fields for each condition in each experiment (C). Asterisks indicate
a relative significant change (P < 0.05) between the indicated bars. Cav3, caveolin-3; GFP, green fluorescent protein.
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observe very similar disturbances in mitochondrial biology to
that seen in Cav3P104L expressing myoblasts (Figures 2 and 3).
Furthermore, analysis of the aggregate to monomer distribu-
tion ratio of JC10, a potentiometric fluorescent dye that accu-
mulates within mitochondria, revealed that compared with
WT cells, this was significantly reduced in shCav3 and Cav3KO
myoblasts (Supporting Information, Figure S2D). This latter
observation implies that Cav3 deficiency is associated with a
marked depolarisation of the mitochondrial membrane po-
tential. A corollary of the observed reduction in proteins that
support mitochondrial biogenesis, morphology, respiratory
function, and adenine nucleotide exchange is that
myoblasts lacking Cav3 are also likely to exhibit an energy
deficit. Consistent with this proposition, the ATP:ADP ratio
was significantly lower in both shCav3 and Cav3KO myoblasts
(Supporting Information, Figure S2E).
Analysis of caveolin-3-knockout mouse muscle
Our cell-based studies show that Cav3 loss is associated with
disturbances in mitochondrial morphology and function that
may be driven, in part, by changes in the expression of key
mitochondrial proteins. To assess whether comparable
Figure 3 Effects of expressing the Cav3P104L mutation on mitochondrial respiration and protein expression in L6muscle cells. Wild-type L6muscle cells
or those stably expressing an empty vector (EV) or one encoding Cav3
P104L
were used for analysis of cell respiration using Seahorse technology. The
oxygen consumption rate (OCR) trace shown in (A) is representative from a single experiment in which each point represents mean ± SEM of a trip-
licate measurement. Oligomycin (1 μM), FCCP (1 μM), and a mixture of Rotenone (1 μM)/Antimycin (2 μM) were added for determination of basal,
ATP-linked, and maximal respiration (B). The abundance of Cav3 and GAPDH (used as loading control) in WT, EV, and Cav3P104L expressing L6 muscle
cells was determined by immunoblotting. The bar graph quantifies Cav3 abundance relative to GAPDH (mean ± SEM) (C). Cytosolic (Cyto, 5 μg protein)
and mitochondrial-enriched fractions (MF, 5 μg protein) from WT, EV, and Cav3P104L expressing myoblasts were immunoblotted with antibodies
directed to the proteins indicated. The Cav3 blots show two separate image exposures. Whole cell lysates (WCL, 30 μg protein) from WT, EV, and
Cav3P104L expressing myoblasts were subject to sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting with antibodies to pro-
teins indicated (D) and their abundance quantified from a minimum of three separate experiments relative to actin (gel loading control) using Image J
software (E). Analysis of superoxide content (F) was determined using fluorescence intensity (FI) of MitoSOX and citrate synthase (CS) activity in myo-
blasts was used as a proxy for mitochondrial mass (G). All graphical data represent mean ± SEM from a minimum of three separate experiments. As-
terisks indicate a significant change (P < 0.05), whereas the NS notation signifies no significant change. Cav3, caveolin-3; SDHA, succinate
dehydrogenase subunit A; MnSOD, manganase superoxide dismutase; WT, wild type; VDAC, voltage-dependent anion channel.
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changes in protein expression are evident in vivo, we
immunoblotted crude homogenates prepared from gastroc-
nemius muscle of WT(+/+) and Cav3KO(/) mice. Unlike
myoblasts, loss of Cav3 in mouse muscle induced a modest,
but significant, compensated increase in Cav1 (Figure 4A
and 4B). Furthermore, while we saw no significant changes
in the expression of MFN2 or OPA1 between muscle from
Cav3(+/+) and Cav3(/) mice, there was a robust increase in
the abundance of Drp1, a profission protein and notable loss
of SDHA and COX IV (two key respiratory proteins) and that
of MnSOD, ANT1 and PGC1α (Figure 4A and 4B). Consistent
with our cell-based data (Supporting Information, Figure
S2), the expression of TOM20 and VDAC was unaffected by
loss of Cav3 in mouse muscle (Figure 4A and 4B).
The reduced expression of respiratory proteins in muscle
of Cav3KO mice may suggest a decline in respiratory
drive/mitochondrial mass. While we did not validate whether
mitochondrial respiration was impaired in intact mitochon-
dria isolated from skeletal muscle of Cav3/ mice, a dimin-
ished mitochondrial function/mass will have implications for
energy-demanding processes such as protein synthesis whose
reduction may contribute to the degeneration and weakness
of muscle reported in these mice.15,33,34 Consistent with this
proposition, analysis of mitochondrial density (as judged by
measurement of mitochondrial DNA and CS activity) and total
muscle protein expressed per milligram of muscle weight re-
vealed these were significantly reduced by ~22% and 35%, re-
spectively, in gastrocnemius muscle of Cav3/ mice (Figure
4C and 4D).
Effects of caveolin-3 deficiency on cellular protein
synthesis
To assess whether the reduced mitochondrial density and en-
ergy balance seen in Cav3P104L and Cav3KO myoblasts com-
promises the activity of energy-demanding processes, we
assessed cellular protein synthesis using the non-isotopic
SUnSET technique,43 which assays incorporation of puromy-
cin into newly synthesized polypeptides. Figure 5A and 5B
show that the abundance of puromycylated proteins in
Cav3P104L expressing myoblasts or that in Cav3KO myoblasts
was notably lower compared with that seen in WT L6 myo-
blasts. As expected, prior treatment of L6 myoblasts with cy-
cloheximide inhibits protein synthesis as judged by the
striking reduction in puromycylation (compare Lanes 2 and
3 in Figure 5A and 5B). In line with the lower protein synthe-
sis, total protein content in Cav3P104L expressing myoblasts or
Figure 4 Effects of Cav3 deficiency upon proteins linked to mitochondrial function and upon mitochondrial mass in mouse skeletal muscle. Crude mus-
cle homogenates prepared from gastrocnemius muscle of three wild type (WT, +/+) and three Cav3 knockout (Cav3KO, /) mice were subject to
sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotted with antibodies to proteins shown (A) and protein abundance quanti-
fied relative to actin (used as a gel loading control) using Image J software (B). The data in (B) (mean ± SEM) is based on analysis of five WT and five
Cav3KO mice. Alternatively, muscle tissue from mice was used for analysis of mitochondrial DNA or citrate synthase activity (C) or total muscle protein
(D) as described in the methods section. Values in (C and D) are expressed as mean ± SEM from a minimum of three mice. Asterisks indicate a signif-
icant change (P < 0.05) to the appropriate WT data or between the indicated bars. Cav3, caveolin-3; SDHA, succinate dehydrogenase subunit A;
MnSOD, manganase superoxide dismutase; WT, wild type; VDAC, voltage-dependent anion channel.
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that in Cav3KO myoblasts was significantly less compared
with of WT myoblasts when assessed using equivalent myo-
blast numbers for the protein assay (Figure 5C).
Cellular re-expression of caveolin-3 in a caveolin-3
null background rescues the loss in mitochondrial
morphology and respiratory function
Given that Cav3 loss is associated with increased fragmenta-
tion of the mitochondrial network and reduced mitochondrial
respiratory function, we subsequently assessed if this could
be mitigated by ectopic re-expression of WT Cav3 into a
Cav3 null background. For these studies, we transiently
transfected mCherry-WT-Cav3 (or the empty mCherry vector)
into myoblasts in which Cav3 had been deleted by
CRISPR/Cas9 prior to mitochondrial staining and live cell im-
aging. Mitotracker labelling highlighted a predominantly
(~75%) elongated and tubular mitochondrial network in
WT L6 myoblasts. By contrast, the mitochondrial network
was largely fragmented in Cav3KO cells irrespective of
whether they had been transfected with the empty mCherry
vector (red labelled myoblasts) or not (non-labelled cells).
Strikingly, however, Cav3KO myoblasts that had been suc-
cessfully transfected with the mCherry-WT-Cav3 (i.e. those
staining red) exhibit mitochondria that were part of an
elongated/tubular network that had some semblance of that
observed in WT cells. Importantly, neighbouring myoblasts
that had not been transfected/labelled with the mCherry-
WT-Cav3 vector still retained the highly fragmented mito-
chondrial morphology (Figure 6A and 6B).
To determine whether expression of key mitochondrial
proteins and respiratory function could be rescued by re-
expression of Cav3, we generated a stable Cav3KO myoblast
line in which an HA-GFP-tagged WT-Cav3 was reintroduced.
Figure 7A shows that we were able to detect an immunore-
active Cav3 band (~50 kDa) that corresponds to the HA-GFP-
tagged WT-Cav3, which was not seen in cell lysates from
WT, Cav3KO, or Cav3KO cells expressing the empty vector
(EV). The immunoreactive intensity of the 50 kDa band
was similar to that of the native Cav3 band (at ~20 kDa)
present in WT myoblasts suggesting Cav3 re-expression in
the null background was similar to that of WT cells. Immu-
noblotting cytosolic and mitochondrial fractions revealed
that this re-expressed HA-GFP-tagged Cav3 was detectable
in the mitochondrial fraction (Figure 7B) and importantly re-
stored expression of OPA1, MFN2, SDHA, ANT1, PGC1α, and
MnSOD to levels that were comparable with that seen in
WT-L6 myoblasts (Figure 7C). As such, these changes were
associated with a lowering of superoxide levels, restoration
Figure 5 Cav3 depleted cells exhibit reduced protein synthetic capacity. For analysis of protein synthesis, wild-type L6 myoblasts stably expressing an
empty vector (EV) or one encoding Cav3 P104L or myoblasts in which Cav3 was deleted using CRISPR/Cas9 (Cav3KO) were incubated in the absence or
presence of puromycin for 15 min (Lanes 2–7) or subject to pre-treatment with cycloheximide for 15 min prior to puromycin exposure [Lanes 2, 4, and
6 in (A) and Lanes 2 and 4 in (B)]. Following treatment, myoblasts were lysed and lysates (30 μg protein) from (A) WT, WT + EV, Cav3 P104L expressing
or (B) Cav3KO myoblasts were subject to sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting with antibodies to puromycin
and GAPDH and their abundance quantified from three separate experiments relative to GAPDH (a gel loading control) using Image J software. For total
protein content 104 myoblasts (WT, EV, P104L, and Cav3KO) were counted and protein assessed using the Bradford method and expressed as μg/104
cells (C). All bar graph data represent mean ± SEM from three separate experiments. Asterisks indicate a significant change (P < 0.05). CHX, cyclohex-
imide; EV, empty vector; WT, wild type.
12 D.S. Shah et al.
Journal of Cachexia, Sarcopenia and Muscle 2020
DOI: 10.1002/jcsm.12541
of mitochondrial membrane potential (Figure 7D), and im-
proved respiratory function as assessed using Seahorse tech-
nology (Figure 7E).
Caveolin-3 deficiency modifies myocellular
mitochondrial cholesterol and cardiolipin content
Given the important role that Cav plays in cellular cholesterol
homeostasis, we postulated that Cav3 deficiency induced by
expression of Cav3P104L or by use of CRISPR/Cas9 gene editing
may affect cholesterol content of muscle cells. In line with
this, we observed a 57% and 82% increase in whole cell cho-
lesterol in Cav3P104L and Cav3KO myoblasts, respectively,
(Figure 8A). Analysis of cholesterol content in isolated mito-
chondrial membrane fractions from these myoblasts revealed
that it too was elevated in response to Cav3 deficiency. The
increase in both whole cell and mitochondrial cholesterol
was negated by re-expression of Cav3 in Cav3KO myoblasts
(Figure 8A).
Cardiolipin is a unique phospholipid located in the inner
mitochondrial membrane, and its loss has been linked to mi-
tochondrial dysfunction and a decline in muscle mass and
strength.48 To assess whether cardiolipin content is sensitive
to changes in Cav3 expression, we stained myoblasts with
10-N-nonyl acridine orange, a fluorescent cardiolipin
indicator. Cardiolipin abundance was reduced significantly
in both Cav3P104L expressing myoblasts (by 43%) and Cav3KO
muscle cells (by 62%) when quantified either per unit of cell
protein or as a ratio to the fluorescence intensity of
mitotracker (Figure 8B). This reduction in cardiolipin was
mitigated upon stable re-expression of Cav3 (Figure 8B).
The presence of cardiolipin in the inner mitochondrial mem-
brane is dependent upon a number of key biosynthetic en-
zymes such as tafazzin, phosphatidylgycerol phosphate
synthase, phosphatidylglycerophosphate and protein–
tyrosine phosphatase 1, cytidylyltransferase-diacylglycerol
synthase activity, and cardiolipin synthase. qPCR analysis
assessing expression of genes encoding these enzymes indi-
cated a significant decline in mRNA for tafazzin, PMTM1,
and cardiolipin synthase in Cav3-deficient myoblasts,
whereas that for phosphatidylgycerol phosphate synthase
and cytidylyltransferase-diacylglycerol synthase was unaf-
fected (Figure 8C).
Discussion
Previous work has shown that the LGMD1C Cav3P104L muta-
tion is associated with aberrant accumulation of the mutant
Cav3 protein within the Golgi where it forms unstable high
Figure 6 Effects of Cav3 re-expression on mitochondrial morphology in L6 muscle cells. Myoblasts in which Cav3 had been deleted by CRISPR/Cas9
(Cav3KO) were transiently transfected with either a control mCherry empty vector or a mCherry vector encoding wild-type Cav3 prior to staining with
Mitotracker Green and imaging by confocal microscopy and comparative analysis with Mitotracker stained wild type myoblasts (WT). Images depict
mitochondrial morphology in L6myoblasts from WT and Cav3KO cells. Myoblasts that were transiently transfected and expressing the mCherry appear
red. The fields contained within the white boxes have been are enlarged to highlight differences in morphology. White arrow heads draw attention to
changes mitochondrial morphology of interest. Mitochondrial length in WT cells and Cav3KO cells in which the empty vector or that containing the WT-
Cav3 insert was measured using Volocity software and judged as tubular/elongated if greater than 1 μm in length and fragmented if less than 1 μm. In
addition, cells within the same assay that had not taken up the mCherry vector were also used for comparative measurement of mitochondrial length
and compared against WT and transfected cells. Data in the bar chart are presented as mean ± SEM from three separate experiments in which at least
12 randomly chosen visual fields were analysed. Asterisks indicate a significant change (P < 0.05) between the indicated bars.
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molecular mass aggregates with wild type Cav3 and is subse-
quently targeted for degradation by the proteasome.45 A
more recent study utilizing a transgenic Cav3 (p.P104L mu-
tant) mouse model showed that such aggregation was a con-
sequence of impaired ER-Golgi protein processing, which,
from proteomic profiling, was found to also affect proteins
important for maintaining the integrity of the cytoskeleton,
extracellular matrix, sarcolemma, and mitochondria.11 How-
ever, while this latter study detected changes in a total of
26 different mitochondrial proteins in muscle from p.P104L
mice, no functional studies of mitochondrial respiration were
performed. The work reported here demonstrates for the
first time that (i) Cav3 appears to be closely associated with
mitochondrial membranes prepared from mouse skeletal
muscle and L6 myoblasts, (ii) loss of Cav3 in myoblasts ex-
pressing the P104L mutant or those in which the Cav3 gene
has been silenced/deleted is associated with increased frag-
mentation of the mitochondrial network and a reduction in
mitochondrial mass, (iii) that Cav3 loss induces deleterious
changes in the expression of proteins regulating mitochon-
drial dynamics, redox status and respiratory function, and
(iv) re-expression of Cav3 in Cav3 deficient myoblasts not
Figure 7 Effects of Cav3 re-expression on mitochondrial protein expression, membrane potential, superoxide and mitochondrial respiration. Myoblasts
in which Cav3 had been deleted by CRISPR/Cas9 (Cav3KO) were infected with retroviral particles containing an empty vector (Cav3KO + EV) or a vector
containing HA-GFP tagged WT-Cav3 (Cav3KO + Cav3) and stable transformants isolated by antibiotic selection prior to: (A) immunoblotting whole cell
lysates (WCL) with antibodies against Cav3 or actin (used as a gel loading control) antibodies; (B) isolation of cytosolic (Cyto) and mitochondrial
membranes and immunoblotting using antibodies to proteins indicated; (C) lysis and immunoblotting of WCL with antibodies to proteins shown
and quantification of their abundance relative to GAPDH (used as a gel loading control) using Image J software; (D) determination of superoxide con-
tent using fluorescence intensity (FI) of MitoSOX and mitochondrial membrane potential monitored by spectral analysis of JC-10 aggregate:monomer
content from three separate experiments (for this experiment GFP would interfere with the JC-10 probe and therefore wild type Cav3 was cloned into
pcDNA3.1 using HindIII and XhoI Restriction sites and an empty vector or a vector containing Cav3 were transiently transfected in L6 muscle cells and
selected for using G418 before JC-10 probe incubation); and (E) analysis of mitochondrial respiration to assess basal oxygen consumption rate using
Seahorse technology. Oligomycin (1 μM), FCCP (1 μM) and a mixture of Rotenone (1 μM)/Antimycin (2 μM) were added at the times indicated by
dotted lines to determine basal, ATP-linked and maximal respiration. The Seahorse trace shown in (E) is from a single experiment in which each point
represents the mean ± SEM from triplicate analyses. All bar graph data in (E) represent the analysis of three individual experiments (values are mean ±
SEM). Asterisks indicate significant change (P < 0.05) to the WT bar value or between indicated bars. Cav3, caveolin-3; EV, empty vector; SDHA, suc-
cinate dehydrogenase subunit A; WT, wild type; VDAC, voltage-dependent anion channel.
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only promotes reformation of a tubular mitochondrial net-
work but is also associated with improved mitochondrial re-
dox status and respiratory function.
Although Cav1 immunoreactivity was detectable in crude
homogenates prepared from mouse skeletal muscle, its
abundance is substantially lower than that of Cav3, which is
widely regarded as the principal Cav isoform in muscle22,49
and, consequently, the one most likely to be of functional im-
portance in this tissue. Consistent with this view, our data in-
dicate that while Cav3P104L induces a marked decline in total
myocellular Cav3 and profound changes in mitochondrial
morphology and function, it had little impact upon the abun-
dance of Cav1. This observation implies that Cav1 is unlikely
to substitute for Cav3 in skeletal muscle cells, at least in terms
of helping to preserve mitochondrial integrity and function.
This proposition is further supported by the fact that Cav1
was barely detectable in isolated mitochondrial fractions
from mouse skeletal muscle and that myoblasts in which
Cav1 has been deleted by CRISPR/Cas9 do not show any
significant decline in cell respiration ( Supporting Information,
Figure S5). However, it is noteworthy that while Cav1 appears
dispensable for regulation of myocellular respiration, Cav1
loss in non-muscle cell types (e.g. adipose tissue and mouse
embryonic fibroblasts)50–52 has been linked to impaired mito-
chondrial function indicating that cell respiration and energy
metabolism may be regulated in different tissues in a Cav
isoform-specific manner.
The reduced mitochondrial respiratory capacity associated
with Cav3 deficiency is most likely the consequence of a num-
ber of factors, including a decline in mitochondrial mass that
occurs in skeletal muscle of Cav3/ mice and myoblasts ex-
pressing Cav3P104L. This reduction in mitochondrial mass may
be linked to changes in PGC1α, a key regulator of mitochon-
drial biogenesis, whose abundance was diminished in muscle
of Cav3/mice and L6myoblasts in which Cav3 had been re-
pressed by three different genetic approaches. PGC1α regu-
lates the activity of several nuclear transcription factors,
including the nuclear respiratory factors (NRF1 and NRF2)
Figure 8 Effects of cellular Cav3 loss and Cav3 re-expression on cholesterol and cardiolipin content in L6 muscle cells. Wild-type (WT) L6 myoblasts or
those transfected with an empty vector (EV) or stably expressing the Cav3P104L LGMD1C mutation, or those in which Cav3 had been deleted by
CRISPR/Cas9 (Cav3KO) and in which Cav3 was subsequently stably re-expressed (Cav3KO + Cav3) were used to determine: (A) whole cell cholesterol
(expressed relative to that assayed in WT cells) or cholesterol content of isolated mitochondrial membranes (expressed per unit protein content); (B)
cardiolipin content using 10-nonyl-acridine orange (a cardiolipin probe) and mitotracker deep red prior to live cell confocal imaging (in which a minimum
of 12 randomly chosen fields were chosen in three biological repeats) or quantification of fluorescence emission using a plate reader from three separate
experiments each conducted in triplicate. The fluorescence intensity of cardiolipin in each cell condition was normalized to that of mitotracker for con-
focal-based analysis or to protein content for plate reader-based analysis; (C) expression of enzymes involved in cardiolipin biosynthesis in each cell con-
dition was determined by quantitative polymerase chain reaction. All data are expressed as mean ± SEM from aminimum of three separate experiments.
Asterisks indicate a significant change (P< 0.05) to theWT (control) value. PTPMT1, phosphatidylglycerophosphate and protein-tyrosine phosphatase 1.
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and the oestrogen-related receptor α that, in turn, regulates
expression of OXPHOS genes (e.g. cytochrome c, SDHA), mi-
tochondrial uncoupling proteins (i.e. UCP3), ANT1, subunits
of the mitochondrial ATP synthase, and ROS-detoxifying en-
zymes.47,53,54 Consequently, the reduced transcriptional acti-
vation of genes encoding these functionally important
mitochondrial proteins will impact negatively upon mitochon-
drial density and upon substrate (i.e. glucose) oxidation and
ATP synthesis that is linked to electron transport chain
(ETC) activity. In support of this proposition, we see a sub-
stantial decline (~70%) in the ATP:ADP ratio in Cav3KO myo-
blasts (Supporting Information, Figure S2E) and also find
that while oxidation of glucose in WT myoblasts accounts
for ~60% of ATP production, it only supports 20% of ATP-
linked respiration in Cav3KO myoblasts (Supporting Informa-
tion, Figure S6A). It is possible that Cav3 deficiency may in-
duce a metabolic shift towards greater anaerobic
respiration, but analysis of the extracellular acidification rate,
which is an indicative measure of lactate output and glyco-
lytic flux, reveals that it too was significantly lower in Cav3KO
myoblasts (Supporting Information, Figure S6B). These find-
ings collectively signal that the decline in mitochondrial respi-
ration in Cav3-deficient myoblasts is associated with reduced
demand for glucose as a metabolic fuel and is consistent with
work showing that myoblasts expressing Cav3P104L exhibit di-
minished glucose uptake.18
Modulation of mitochondrial dynamics may also influence
respiratory function. Cav3 loss in myoblasts promotes a strik-
ing shift in mitochondrial morphology from a tubular network
to one that was highly fragmented. While fission is physiolog-
ically important for maintaining mitochondrial quality control,
excessive fragmentation of the mitochondrial network (due to
increased fission and/or reduced mitochondrial fusion) results
in accumulation of dysfunctional mitochondria, which, if func-
tionally unrecoverable, are normally cleared by mitophagy.
However, experiments assessing expression of a
bifluorescent-labelled (mCherry-GFP) mitophagy reporter55,56
in WT and Cav3KO myoblasts indicate that mitophagy was re-
duced (~20%) in Cav3KO myoblasts (Supporting Information,
Figure S7). The reasons for this are currently unclear, but
given that mitophagy represents selective degradation of mi-
tochondria by autophagy and the latter process has significant
energy and synthetic requirements, it is plausible that the en-
ergy deficit within Cav3KO cells compromises the effective
clearance of damaged mitochondria.
Mitochondria are also the principal source of ROS (superox-
ide and hydrogen peroxide, H2O2) that are generated by re-
duction of oxygen by electrons ‘leaking’ from within the ETC
during OXPHOS.57 In healthy cells, ROS production is normally
low and rapidly neutralized by ROS detoxifying enzymes such
as MnSOD. However, ROS generation can exceed the anti-
oxidant capacity of cells in numerous circumstances as seen,
for example, during periods of excessive mitochondrial fuel
supply and/or conditions that reduce expression/activity of
anti-oxidant enzymes.56 Our work indicates that muscle of
Cav3/mice andmyoblasts expressing Cav3P104L or those ge-
netically depleted in Cav3 exhibit a significant reduction in
MnSOD, which may contribute to the rise in mitochondrial su-
peroxide. ETC components are very sensitive to reactive
oxygen-derived radicals, and their operational efficiency is
not only reduced by oxidative stress but may further exacer-
bate ROS production that feeds a viscous cycle inducing ever
greater mitochondrial dysfunction. This increased oxidative
stress may also drive the observed changes in mitochondrial
integrity and morphology. Previous work in C2C12 myoblasts
has shown that acute exposure to H2O2 initiates mitochon-
drial fragmentation and that this is preceded by
depolarisation of the mitochondrial membrane and a reduc-
tion in maximal respiration.58 Mitochondrial fragmentation is
also a feature of muscle cells subjected to sustained fuel
overloading.56 Interestingly, this fragmentation can be ame-
liorated by cell treatment with MitoTempo, a mitochondrial-
targeted superoxide scavenger. Notably, while mitochondrial
fission is blunted by MitoTempo in fuel-overloaded myotubes,
it fails to mitigate the associated loss in mitochondrial respira-
tory capacity, which is likely sustained because of the failure
to recover expression of key functional proteins, such as
SDHA, ANT-1, and UCP3.56 Based on these latter observations,
the increase in oxidative stress seen in Cav3P104L expressing
myoblasts (and that reported in numerous muscular dystro-
phies59) may be important in influencing the morphology of
the mitochondrial network. This possibility is supported by
growing evidence linking changes in ROS to regulation of mito-
chondrial dynamics via non-transcriptional modulation (e.g.
phosphorylation, ubiquitination, and S-nitrosylation) of mito-
chondrial fusion and fission proteins.60 Important in this con-
text is the impact that an increase in superoxide in Cav3
depleted myoblasts may have upon proteins regulating mito-
chondrial dynamics. Myoblasts expressing Cav3P104L (or those
in which Cav3 was repressed by shRNA or CRISPR/Cas9) dis-
play a significant loss in both MFN2 and OPA1, whereas skel-
etal muscles of Cav3/ mice exhibit a two-fold increase in
Drp1. In either case, the observed changes would be consis-
tent with a shift in mitochondrial dynamics towards greater
fission. Whether this shift involves ROS-mediated regulation
of MFN2, OPA1, or Drp1 via changes in gene expression
and/or post-transcriptional modulation is currently unknown,
but addressing this issue and how it might mechanistically link
to changes in Cav3 expression represent important investiga-
tive goals of future work.
Although the cholesterol content of mitochondrial mem-
branes is substantially lower than that of plasma mem-
branes,61 it fulfils a vital role in their biogenesis,
maintenance and membrane fluidity. Caveolins bind choles-
terol with high affinity and play an important role in control-
ling cholesterol trafficking between multiple subcellular
compartments, including mitochondria.22 Consequently, al-
tered Cav expression/function may disturb intracellular
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trafficking/storage of cholesterol and partly be a cause for mi-
tochondrial dysfunction. In line with this view, our results
show that myoblasts expressing Cav3P104L or those lacking
Cav3 exhibit raised whole cell cholesterol that was also evi-
dent in mitochondrial membranes. While this increase may
partly be linked to a loss in Cav-dependent trafficking of the
sterol through mitochondria, previous work by Bosch and co-
workers has shown that mitochondrial cholesterol is also ele-
vated in mouse embryonic fibroblasts lacking Cav1 despite
there being no apparent localization of Cav1 in mitochondria
in these cells.51 However, Cav1 does localize to specialized
domains of the ER called mitochondrial associated mem-
branes (MAMs) that potentially serve as foci for the move-
ment of ions and lipids, including cholesterol, between the
ER and mitochondria.62 Resident Cav1 would normally facili-
tate efflux of newly synthesized ER cholesterol to the plasma
membrane, whereas Cav1 loss from MAMs would result in
greater cholesterol ‘spillage’ to mitochondria. While we can-
not fully exclude the possibility that the Cav3 we detect in
our mitochondrial-enriched fractions may also be of MAM or-
igin, this seems unlikely given that, unlike VDAC or TOM20,
these membrane fractions show no significant enrichment
of BiP/GRP78, an ER marker protein. Regardless of whether
Cavs are resident in mitochondria or MAMs, Bosch et al.
showed that the increased mitochondrial cholesterol reduced
mitochondrial membrane fluidity and, as shown in the cur-
rent study, reduced respiratory activity and increased ROS
production, which the authors attributed to a reduction in
mitochondrial anti-oxidant capacity.51 Significantly, the dis-
turbances in cholesterol content, redox status, and mitochon-
drial function reported by Bosch et al. in Cav1-deficient
MEFs51 and by us in Cav3-deficient myoblasts are recoverable
upon cellular re-expression of the respective Cav isoform.
Furthermore, in our hands, this recovery not only involves
restoration of the mitochondrial membrane potential but
also reformation of the tubular mitochondrial network that
is most likely facilitated by restraining loss of MFN2 and
OPA1 that is otherwise seen in Cav3-deficient myoblasts.
Another critical regulator of mitochondrial form and func-
tion is cardiolipin, a signature phospholipid found almost ex-
clusively in the inner mitochondrial membrane where it
plays a key role in many mitochondrial processes, including
formation of cristae in the inner membrane, regulating the
organization and activity of respiratory chain complexes
and that of transporters (e.g. ANT-1) and the ATP syn-
thase.63,64 A reduction in cardiolipin has been linked to mito-
chondrial dysfunction in numerous tissues, and our study
reveals, for the first time, that this reduction is also a fea-
ture of myoblasts expressing the LGMD1C Cav3P104L muta-
tion and those in which the Cav3 gene has been deleted.
Precisely how loss of Cav3 in myoblasts drives cardiolipin
loss is unclear, but this decline may be linked to reduced ex-
pression of enzymes involved in its biosynthesis but also
possibly its increased degradation. Cardiolipin is highly
susceptible to ROS attack, and its peroxidation, as would
be anticipated under conditions of heightened ROS genera-
tion, enhances its breakdown.65 Our work indicates that
re-expression of Cav3 not only mitigates the increase in
ROS production but also normalizes expression of genes
encoding cardiolipin synthase, protein–tyrosine phosphatase
1 and taffazin in Cav3KO myoblasts, which may collectively
help restore cardiolipin content and improve mitochondrial
integrity and function. Given the central role that cardiolipin
plays in supporting a multitude of mitochondrial processes,
there is considerable interest in exploiting this phospholipid
as a drug target, especially in conditions where there is a
deficit in mitochondrial energy production (e.g. skeletal mus-
cle weakness, heart failure, and neurodegenerative disease).
One potential therapeutic strategy involves use of Szeto-
Schiller peptides, which are small synthetic tetrapeptides
that specifically target the activity of mitochondrial cyto-
chrome c to inhibit cardiolipin peroxidation. These
cardiolipin-protective peptides have been shown to rejuve-
nate mitochondrial OXPHOS components, stimulate ATP pro-
duction, and reduce electron ‘leakage’ from within the ETC
and consequently ROS generation.66,67 Whether cardiolipin
loss serves as the primary trigger for the mitochondrial dys-
function we observe in myoblasts expressing Cav3P104L is
currently unknown, but assessing whether such peptide-
based interventions can attenuate the deleterious changes
in mitochondrial morphology and function seen in these
myoblasts is clearly worthy of further investigation.
In summary, our data reveal that Cav3 expression in skel-
etal muscle cells is an important regulator of mitochondrial
homeostasis and that its loss, induced either by expression
of the LGMD1C Cav3P104L mutation or by targeted Cav3
gene silencing/deletion, reduces mitochondrial mass and
promotes a profound morphological change in the mito-
chondrial network that impairs mitochondrial respiration
and redox status. However, it is also important to stress that
Cav3 loss in muscle cells induced by the above approaches
has been shown to impair myoblast fusion and differentia-
tion.37–39 Consequently, a potential limitation of the
in vitro studies reported here is that because they were per-
formed in myoblasts, this may have translational implica-
tions for understanding how muscle physiology is affected
in patients presenting with caveolinopathies, such as
LGMD1C. Whether Cav3 deficiency slows the process of
myotube formation in vivo or modifies muscle fibre-type
composition is currently unknown, but it is noteworthy that
studies utilizing a zebrafish model in which Cav3 was down-
regulated or the equivalent Cav3P104L mutation was
expressed display significant in vivo defects in myoblast fu-
sion, muscle differentiation, and patterning during early de-
velopment.68 Because myoblast fusion is an important
determinant of muscle fibre size and Cav3 deficient mice
have been shown to not only exhibit greater variability in fi-
bre size but also increased fibre necrosis,33 it is plausible
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these myopathic changes are a consequence of maintaining
the immature cell signature that has been identified in vitro
in myoblasts expressing the P104L mutation.37 It is also con-
ceivable that disturbances in mitochondrial biology and en-
ergy metabolism that we see associated with Cav3-
deficiency in myoblasts and mice contribute to the reduced
fusion potential of myoblasts in vitro and to ultrastructural
changes in muscle in vivo.13,34 Whether skeletal muscle of
LGMD1C patients also exhibit similar changes in mitochon-
drial biology is currently unknown, but testing this would
be instructive not only for establishing the utility and rele-
vance of myoblasts as a disease model but also for assessing
whether impaired mitochondrial energetics/ATP production
might contribute to muscle atrophy and the decline in mus-
cle strength and exercise tolerance that has been reported
in patients with caveolinopathies.69
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Figure S1: Cav3 Co-localises with mitochondria in L6 Muscle
cells. Wild type (WT) L6 myoblasts stably transfected with
WT-Cav3-GFP were stained with Mitotracker DeepRed and
visualised using live cell confocal microscopy. Enlarged images
(derived from the fields within the indicated white boxes)
show co-localisation (highlighted by white arrows) of WT-
Cav3-GFP signal and Mitotracker Deep Red signal.The images
are representative of two separate experiments.
Figure S2: Cellular depletion of Cav3 induces changes in mi-
tochondrial protein content, superoxide, membrane poten-
tial and ATP:ADP ratios. Whole cell lysates (WCL, 30 μg
protein) from WT L6 myoblasts, short hairpin control
(ShControl) stable transfected, or those in which Cav3 had
been stably silenced using shRNA (shCav3) or deleted using
CRISPR/Cas9 (Cav3KO) were subject to SDS-PAGE and
immunoblotted with antibodies to proteins shown (A) and
their abundance quantified from a minimum of three sepa-
rate experiments relative to actin (gel loading control) using
Image J software (B). Alternatively, these cells were used
for determination of superoxide content using fluorescence
intensity (FI) of MitoSOX (C) and mitochondrial membrane
potential using spectral analysis to monitor JC-10 aggregate:
monomer content from three separate experiments each
conducted in triplicate. For these studies 5 μM FCCP was
used as a positive control to help collapse the mitochondrial
membrane potential (D) or for analysis of cellular ATP:ADP ra-
tio (E). All graphical data represent mean ± SEM from three
separate experiments. Asterisks indicate a significant change
(P < 0.05), whereas the NS notation signifies no significant
change. For analysis of ATP:ADP ratio muscle cells were
grown to confluence in 6 cm culture dishes and prior to anal-
ysis of ATP and ADP washed with ice-cold PBS. Cells were
lysed in 5% (v/v) perchloric acid (PCA) and the samples were
mixed to ensure complete lysis. Lysed cells were centrifuged
at 18,000g for 3 min at 4°C and the supernatant used for fur-
ther processing. PCA was neutralised with 2.5 M KOH in 1.1
M K2HPO4, after which the neutralised sample was mixed
and centrifuged at 18,000g for 3 min. Adenine nucleotides
within the supernatant were then separated by capillary elec-
trophoresis with on-column isotachophoretic concentration
using buffers containing 50 mM sodium phosphate, 50 mM
sodium chloride (pH 5.2; initial buffer) and 100 mM
MES/Tris (pH 5.2; trailing buffer). To each buffer, 0.2%
hydroxyethylcellulose was added to decrease electro osmotic
flow. Nucleotide peaks were detected by UV absorbance at
260 nm and integrated using System Gold software. Peak
areas, after correction of retention times, were used to calcu-
late ratios. Retention times of ATP and ADP peaks were con-
firmed with samples spiked with internal standards (ATP and
ADP) and analysis of the spectral absorbance of individual
peaks.
Figure S3: Effect of Cav3 loss on mitochondrial morphology
in L6 myoblasts. WT L6 myoblasts or those transfected with
a control shRNA and ShCav3 targeting and causing stable
silencing of Cav3, or myoblasts subject to CRISPR/Cas9 to
delete Cav3 (Cav3KO) were stained with Mitotracker Green
prior to live cell confocal imaging to depict mitochondrial
morphology. Enlarged images (derived from the fields within
the indicated white boxes) highlight changes in mitochon-
drial morphology. Mitochondrial length was quantified using
Volocity software and presented as elongated/tubular if
greater than 1 μm and fragmented if less than 1μm in
length. Data are presented as mean ± SEM from a minimum
of three experiments in which at least 10 randomly chosen
visual fields for each condition were analysed. Asterisks indi-
cate a significant change (P < 0.05) between the black-filled
bars.
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Figure S4: The effect of myocellular Cav3 loss on mitochon-
drial respiration. WT L6 myoblasts or those transfected with
a control shRNA or shRNA targeting and causing stable Cav3
loss (ShCav3) (A) or muscle cells subject to CRISPR/Cas9 to
delete Cav3 (Cav3KO) (B) were subject to a ‘mitochondrial
stress test’ in which the basal oxygen consumption rate
(OCR) was measured using Seahorse technology. Oligomycin
(1 μM), FCCP (1 μM) and a mixture of Rotenone (1 μM)/
Antimycin (2 μM) were added at the times indicated by dot-
ted lines to help infer of basal, ATP-linked and maximal respi-
ration. The Seahorse traces shown in A and B are from a
single experiment in which each point represents the mean
± SEM from triplicate analyses. The bar graph data represents
the analysis of three individual experiments (values are mean
± SEM). Asterisks indicate significant change (P < 0.05) be-
tween bars specified.
Figure S5: Effects of Cav1 deficiency on mitochondrial respi-
ration in L6 myoblasts. Wild type (WT) L6 myoblasts and
myoblasts in which Cav1 had been deleted by CRISPR/Cas9
(Cav1 KO) (Sense gRNA: AGTGTACGACGCGCACACCAAGG An-
tisense gRNA: GGTACCGTCTGCTCCACTTACTC) were subject
to a ‘mitochondrial stress test’ using a Seahorse XF24
analyser to allow determination of basal oxygen consump-
tion, ATP-linked respiration and maximal respiration. All data
are presented as mean ± SEM from three experiments. NS in-
dicates no significant change.
Figure S6: Defining the contribution of glucose use for ATP-
linked respiration and analysis of extracellular acidification
rates (ECAR) in wild type and Cav3-deficient L6 myoblastst.
Wild type L6 myoblasts, control short hairpin transfected
(shControl) myoblasts or those in which Cav3 had been sta-
bly silenced by shRNA (shRNACav3) or deleted by
CRISPR/Cas9 (Cav3KO) were used as shown in the two panels
to measure (A) the component of ATP-linked respiration that
was dependent on glucose oxidation or (B) determine extra-
cellular acidification rates (ECAR) as a measure of anaerobic
glycolytic flux using the seahorse XF24 analyser. For the ex-
periment in (A), WT and Cav3KO myoblasts were incubated
in the absence and presence of 20 mM 2-deoxyglucose
(2DG, a glycolytic inhibitor) to assess the effect of blocking
glucose use on the oligomycin-sensitive (i.e. ATP-linked) res-
piration. The experiments in (A) represent data from 5 exper-
imental determinations whereas analysis of ECAR (B) was
based on three experimental determinations. All data are
presented as mean ± SEM. Asterisks indicate significant
change (P < 0.05) between bars specified while NS indicates
no significant change.
Figure S7: Effects of Cav3 depletion on mitophagy in L6
myoblasts. For analysis of mitophagy we infected myoblasts
with a retroviral construct encoding a tandem mCherry-GFP
tag attached to the outer mitochondrial membrane localiza-
tion signal of Fis1 (residues 101–152). In myoblasts express-
ing this construct, mitochondria will fluoresce red and
green. However, upon increased mitophagy, mitochondria
are delivered to lysosomes where the low pH quenches the
GFP signal but not mCherry. Consequently, the degree of
mitophagy in wild type (WT) and Cav3-deficient myoblasts
can be calculated by assessing the relative change in their
red:green signal ratio using fluorescence-activated cell
sorting (FACS), a specialized form of flow cytometry using
the indicated gating strategy (A). WT and Cav3 knockout
(Cav3KO) cell lines infected with the retrovirus containing a
tandem mCherry-GFP protein (selected for using
hygromycin) were utilised for flow cytometry after which
the geometric mean intensity of both mCherry and GFP sig-
nalling was determined and used to calculate the ratio of
mCherry to GFP in both cell lines as an indicator of
mitophagy (B). Data are presented as mean ± SD from two
experiments each with two replicates of 20,000 cells.
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